Delta-plus SARS2 variant spreading so get vaccinated – Scientists



Doctors and scientists, including Dr. Scott Gottlieb, Pfizer board member and former commissioner of the US FDA, have said about the Delta variant of SARS2 that ‘Regions with low vaccination rates will be hardest hit‘.

On Friday the WHO said “Delta is the most transmissible of the variants identified so far. [Delta] has been identified in at least 85 countries, and is spreading rapidly among unvaccinated populations. As some countries ease public health and social measures, we are starting to see increases in transmission around the world. It’s quite simple: more transmission, more variants. Less transmission, less variants,” said WHO officials in a Friday briefing.

Video: British Doctor explains Delta Variant. June 28 DW Interview


On 11 June, Britain reported a new outgrowth of the B 1.617.2 (Delta) variant of the SARS-CoV-2  virus designated as a VOC in India B 1.617.2.1 (Delta-plus or Delta-AY.1).  It has an extra mutation called K417N. The strain has also been reported by India.

Last week the Health Ministry of India said, “Indian SARS-CoV-2 Genomic Consortia has informed that the Delta Plus Variant, currently a Variant of Interest (VOI), has the following characteristics:

  • increased transmissibility,
  • stronger binding to receptors of lung cells, and
  • potential reduction in monoclonal antibody response.”

“B.1.617.2.1, has led to an increase in cases in India. It has also been detected in the U.S., U.K., China, Japan, Poland, Portugal, Russia, and Switzerland,” reports WebMD, a popular medical journal.

Typical response of doctors to the news of the Delta Plus strain of SARS2 is, “There will be variants but stress that the novel coronavirus is fought the same way. Get fully vaccinated.”

Speaking to US TV reporters at NBC News, on Sunday, Dr. Rachael Lee, an assistant professor of medicine at the University of Alabama at Birmingham said, “I think it’s hard for some people to understand that this [COVID-19] has not gone away. And it’s easy to forget that we’re seeing the spread of these variants, and the delta variant in particular.”

Enough time has passed to allow evidence-based research on what has been called the “Delta” variant by the World Health Organization (WHO).

A study conducted by scientists of real world SARS-CoV-2 Delta-variant data versus laboratory studies, was published in the Lancet on 14 June 2021.

What prompted the study was the dominance of the B 1.617.2 (Delta) variant, surpassing the once considered most threatening B.1.1.7 (Alpha) variant, on 19 May 2021, in Scotland.

“We show that the Delta VOC in Scotland was found mainly in younger, more affluent groups. Risk of COVID-19 hospital admission was approximately doubled in those with the Delta VOC when compared to the Alpha VOC, with risk of [hospital] admission particularly increased in those with five or more relevant comorbidities. Both the Oxford–AstraZeneca and Pfizer–BioNTech COVID-19 vaccines were effective in reducing the risk of SARS-CoV-2 infection and COVID-19 hospitalisation in people with the Delta VOC, but these effects on infection appeared to be diminished when compared to those with the Alpha VOC.”  Citing “SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness

“SARS-CoV-2, the virus which causes Covid-19 is evolving and mutating all the time, as do all similar viruses,” Professor Tom Solomon, Director of the Health Protection Research Unit in Emerging and Zoonotic Infections, at the University of Liverpool in Great Britain said.

The Delta Variant is a “suite of nine mutations in the gene encoding spike, the protein that studs the virus’ surface and allows it to invade human cells,” reports science writers Kai Kupferschmidt and Meredith Wadman in Science Magazine. The authors rely on scientific research published here:  “The SARS-CoV-2 variants associated with infections in India, B.1.617, show enhanced spike cleavage by furin ll”

First woman US Vice President Kamala Harris

The first-ever woman US Vice President urges everyone to get fully vaccinated. Vice President of the United States Kamala Harris received her second dose of the Moderna, Inc., COVID-19 vaccine, at NIH on 26 January 2021. Doctors have said about the Delta variant of SARS2 that ‘regions with low vaccination rates will be hardest hit’, insisting that vaccination rates need to be upped.
Photo Credit: NIH/Chiachi Chang
Art/Cropping/Enhancement: Rosa Yamamoto FPMag

On the weekend, FPMag assembled a medical advisory group of three doctors, two nurse practitioners, and one PPE specialist into a Zoom conference.

The most repeated reaction to the Delta variant, was “Fully vaccinate”, referring to the two-inoculation vaccines. “People need to make certain they get their second dose of the vaccine which is needed to respond to the more transmissible and deadly variants,” said Dr. Anderson of The RINJ Foundation.

American Doctor has warned of dense infection outbreaks in areas where vaccination levels are low

“It’s not going to be as pervasive,” Dr. Scott Gottlieb, member of the boards of Pfizer and biotech company Illumina, plus a former commissioner of the US Food and Drug Administration, said Sunday on CBS’s Face the Nation.

“It’s going to hyper-regionalize. There’s certain pockets of the country where you’re going to have very dense outbreaks. Those pockets will be ones with low vaccination rates and low rates of prior infection,” Gottlieb added, “like in many rural and southern communities.”

“This variant is probably 40 to 60% more effective, more contagious, than the B1.1.7 variant, that variant that became prevalent in the United States and caused that surge in the late spring.


SARS2

This transmission electron microscope image shows SARS-CoV-2—also known as SARS2
the virus that causes COVID-19, isolated from a patient in the U.S., emerging from the surface of cells cultured in the lab. Photo Credit: Image captured and colorized at NIAID’s Rocky Mountain Laboratories (RML) in Hamilton, Montana. Photo Credit: NIAID


Wide US Variance in regional vaccination levels creates vulnerabilities, says Pfizer Board Member

“It doesn’t necessarily appear more pathogenic, meaning more dangerous, but it’s infecting people more easily and it’s starting to become very prevalent in the UK in communities that are unvaccinated,” continued Dr. Scott Gottlieb, member of the board of Pfizer and former FDA Czar.

“So kids, for example, young people, seem to be the population that’s spreading it in the United Kingdom. And when we look across the United States, we see wide variance in terms of vaccination rates. Some states like Vermont or Connecticut have very high vaccination rates above 80%. Other states are struggling to get to 50%,” said Dr. Gottlieb about the USA COVID-19 vaccination scene.

“And when you look at the modeling that’s circulating right now among epidemiologists about what we face in the fall, they are predicting that in a scenario where we only get to about 75% of the eligible population vaccinated and have a 60% more transmissible variant, which this new Delta variant may be 60% more transmissible than 1.1.7, they do show an upsurge of infection and reaching a peak of around 20% of the infection that we reached last winter. So about 20% of the peak in January, we will hit in the- in the fall at some point,” said Dr. Gottlieb about the USA COVID-19 situation. (The full transcript is here.)


US President Biden has focussed intently on getting people Vaccinated.

US President Biden at NIH Vaccine Research Center.

File Photo: President Joe Biden visited NIH on February 11, 2021, where he met with leading researchers at the Vaccine Research Center to learn more about the groundbreaking fundamental research that enabled the development of the Moderna and Pfizer COVID-19 vaccines
Pictured left to right: Dr. Barney Graham (NIAID Vaccine Research Center Deputy Director), President Joe Biden, Dr. Anthony Fauci (NIAID Director), Jeffrey Zients (Counselor to the President), Dr. Francis Collins (NIH Director), and Dr. Kizzmekia Corbett (NIAID Vaccine Research Center Senior Research Fellow and Coronavirus Team Lead).
Photo Credit: NIH/Chiachi Chang

Global COVID-19 Data for June 26, 2022

254 Locales report 548,232,792 COVID-19 cases of which there are 16,285,052 active cases, therefore 525,577,822 recoveries and 6,369,918 fatalities.

GMT 2022-06-26 15:21

Data reported should be in accordance with the applied case definitions and testing strategies in each locale as their governments report daily or from time to time. All data researched and published by The RINJ Foundation and partners in CSPaC.

©The RINJ Foundation 2020-2022-06-26T15:21:01Z #Singapore-SK-HUK-77
RINJ is with Civil Society Solidarity Partners against COVID-19.

SARS2 Update 2022-06-26 15:21 GMT

  • Global Population: 7,903,501,966
  • 254 Regions reported 548,232,792 cases
  • 16,285,052 cases active
  • 6,369,918 people reported killed by COVID-19
  • 1.16% is current Case Fatality Rate (CFR)
  • 525,577,822 survived COVID-19
Beta Technology Global Estimates
  • 38.36% of all humans (3,031,727,339) have been infected
  • 0.63% Global estimated inferred average Infection Fatality Rate (IFR)
    (influenza is .1% or 6 per 100k (2019))
  • 19,103,065 Total deaths (CSPaC.net estimated actual) including errors, unexpected deaths with pneumonia indications with no history, and unreported likely-cause excess deaths such as people who never went to a hospital but had COVID-19 indications but never tested.

See The Lancet estimate of excess mortality from COVID-19 (Download PDF) in 191 countries/territories and 252 subnational units of select countries, from 1 January 2 0 2 0, to 31 December 2 0 2 1.

USA (88,380,921)
  • 145.01% of the USA may have been infected including reported + estimated unreported mild and estimated asymptomatic (482,608,934.15) persons, some of whom may not have been ill in their first course of the disease, but could have spread the disease.
  • 1.19% is USA current Case Fatality Rate (CFR) &
  • 0.27% is estimated inferred average Infection Fatality Rate (IFR)
  • 1,303,044 estimated total COVID-19 deaths including unreported likely-cause excess deaths. According to projections of IHME, IHME calculation of excess deaths is slightly higher than what CSPaC is showing.
  • See The Lancet estimate of excess mortality from COVID-19 (Download PDF) in 191 countries/territories and 252 subnational units of select countries, from 1 January 2 0 2 0, to 31 December 2 0 2 1.

    The American Epicenter has 17.87 % of global 'active' cases (2,909,340 USA / 16,285,052 Global), people infected with COVID-19 now.

Below: CSPAC estimated 2022-06-26 03:02 GMT COVID-19 data for India.

EPICENTER-2: India (43,391,331)

Reported*Cases*Deaths*CFR*Recovered
India43,391,331524,9741.2%42,761,481
*Reported by India but understated.

Note: India's reported death sum and cured data are widely seen among epidemiologists and biostatisticians as unreliable. For example, 3,044,797 is CSPAC estimated sum of deaths while India reports 524,974, creating the largest discepency in the world. India might only report hospital tested cases. Sources among hundreds of nurses and other medical practitioners provide a picture that in summary concludes most cases never present in a hospital especially in northern provinces where health care is less available and utilization is low anyway because of poverty, hence most people die at home in India. This theory could explain discrepancies between reported data and algorithmic estimates.

LocaleCasesDeathsActive
India reported:43,391,331524,974104,876
India estimates:239,954,0603,044,797438,273

Data collected and reported by: Civil Society Solidarity Partners against COVID-19